VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis

Vitamin K is necessary for the carboxylation of clotting factors and matrix Gla protein (MGP). Vitamin K epoxide reductase (VKOR) is the enzyme responsible for recirculation of Vitamin K increasing its tissue availability. Polymorphisms of VKOR may alter the function of MGP, thereby influencing vasc...

Full description

Bibliographic Details
Main Authors: Noha A Osman, Nevine El-Abd, Mohamed Nasrallah
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Saudi Journal of Kidney Diseases and Transplantation
Online Access:http://www.sjkdt.org/article.asp?issn=1319-2442;year=2016;volume=27;issue=5;spage=908;epage=915;aulast=Osman
id doaj-cdb916b4cb3047dda918f43406e0a853
record_format Article
spelling doaj-cdb916b4cb3047dda918f43406e0a8532020-11-24T23:52:58ZengWolters Kluwer Medknow PublicationsSaudi Journal of Kidney Diseases and Transplantation1319-24422016-01-0127590891510.4103/1319-2442.190782VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysisNoha A OsmanNevine El-AbdMohamed NasrallahVitamin K is necessary for the carboxylation of clotting factors and matrix Gla protein (MGP). Vitamin K epoxide reductase (VKOR) is the enzyme responsible for recirculation of Vitamin K increasing its tissue availability. Polymorphisms of VKOR may alter the function of MGP, thereby influencing vascular calcification. We conducted this study to investigate the relationship of VKORC1 gene single nucleotide polymorphisms (SNP′s) to vascular calcification and clinically overt cardiovascular disease in chronic kidney disease (CKD) patients on hemodialysis (HD). The study included 54 CKD patients on HD. We excluded those with diabetes or on anticoagulant therapy. Vascular calcifications were measured using computerized tomography scans and roentgenograms. Prevalent clinically overt cardiovascular disease was reported based on the evidence of documented preexisting major cardiovascular events. Genotype detection for the gene VKORC1 C1173T and G-1639A polymorphisms was carried out by polymerase chain reaction. We found a significant association between C1173T polymorphisms and vascular calcification (odds ratio [OR] = 43, P = 0.001). The mutant T allele was also linked with higher odds of vascular calcification (OR = 8.880, 95% confidence interval [CI] = 3.1-25.4, P = 0.001) and clinically overt cardiovascular disease (OR = 4.7, 95% CI = 1.5-14.7, P = 0.005). VKORC1 G-1639A polymorphisms were not associated with vascular calcification and had lower prevalence of clinically overt cardiovascular disease (OR = 0.07, 95% CI = 0.01-0.4, P = 0.001). In patients with CKD on HD, we found that VKORC1 gene polymorphisms did have an association with prevalent cardiovascular calcification and clinically overt cardiovascular disease, C1173T polymorphisms with higher risk for disease, and G-1639A with lower risk.http://www.sjkdt.org/article.asp?issn=1319-2442;year=2016;volume=27;issue=5;spage=908;epage=915;aulast=Osman
collection DOAJ
language English
format Article
sources DOAJ
author Noha A Osman
Nevine El-Abd
Mohamed Nasrallah
spellingShingle Noha A Osman
Nevine El-Abd
Mohamed Nasrallah
VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis
Saudi Journal of Kidney Diseases and Transplantation
author_facet Noha A Osman
Nevine El-Abd
Mohamed Nasrallah
author_sort Noha A Osman
title VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis
title_short VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis
title_full VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis
title_fullStr VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis
title_full_unstemmed VKORC1 gene (vitamin K epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis
title_sort vkorc1 gene (vitamin k epoxide reductase) polymorphisms are associated with cardiovascular disease in chronic kidney disease patients on hemodialysis
publisher Wolters Kluwer Medknow Publications
series Saudi Journal of Kidney Diseases and Transplantation
issn 1319-2442
publishDate 2016-01-01
description Vitamin K is necessary for the carboxylation of clotting factors and matrix Gla protein (MGP). Vitamin K epoxide reductase (VKOR) is the enzyme responsible for recirculation of Vitamin K increasing its tissue availability. Polymorphisms of VKOR may alter the function of MGP, thereby influencing vascular calcification. We conducted this study to investigate the relationship of VKORC1 gene single nucleotide polymorphisms (SNP′s) to vascular calcification and clinically overt cardiovascular disease in chronic kidney disease (CKD) patients on hemodialysis (HD). The study included 54 CKD patients on HD. We excluded those with diabetes or on anticoagulant therapy. Vascular calcifications were measured using computerized tomography scans and roentgenograms. Prevalent clinically overt cardiovascular disease was reported based on the evidence of documented preexisting major cardiovascular events. Genotype detection for the gene VKORC1 C1173T and G-1639A polymorphisms was carried out by polymerase chain reaction. We found a significant association between C1173T polymorphisms and vascular calcification (odds ratio [OR] = 43, P = 0.001). The mutant T allele was also linked with higher odds of vascular calcification (OR = 8.880, 95% confidence interval [CI] = 3.1-25.4, P = 0.001) and clinically overt cardiovascular disease (OR = 4.7, 95% CI = 1.5-14.7, P = 0.005). VKORC1 G-1639A polymorphisms were not associated with vascular calcification and had lower prevalence of clinically overt cardiovascular disease (OR = 0.07, 95% CI = 0.01-0.4, P = 0.001). In patients with CKD on HD, we found that VKORC1 gene polymorphisms did have an association with prevalent cardiovascular calcification and clinically overt cardiovascular disease, C1173T polymorphisms with higher risk for disease, and G-1639A with lower risk.
url http://www.sjkdt.org/article.asp?issn=1319-2442;year=2016;volume=27;issue=5;spage=908;epage=915;aulast=Osman
work_keys_str_mv AT nohaaosman vkorc1genevitaminkepoxidereductasepolymorphismsareassociatedwithcardiovasculardiseaseinchronickidneydiseasepatientsonhemodialysis
AT nevineelabd vkorc1genevitaminkepoxidereductasepolymorphismsareassociatedwithcardiovasculardiseaseinchronickidneydiseasepatientsonhemodialysis
AT mohamednasrallah vkorc1genevitaminkepoxidereductasepolymorphismsareassociatedwithcardiovasculardiseaseinchronickidneydiseasepatientsonhemodialysis
_version_ 1725471208537849856